Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.49 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | HSD17B13 | Q7Z5P4 | 6/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18945874 | 0.88 | CRBN (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL283372 | 0.88 | CRBN (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18904292 | 0.77 | DDB1 (0.38) | DDB1CRBNIKZF3PARP1HSD17B13 | |
| SCHEMBL16587068 | 0.76 | CLK1 (0.46) | PARP1HSD17B13 | |
| SCHEMBL18945869 | 0.74 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL282494 | 0.74 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18509320 | 0.74 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26672049 | 0.74 | CRBN (0.64) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26043078 | 0.74 | DDB1 (0.48) | DDB1CRBNIKZF3PARP1TNF | |
| SCHEMBL13871000 | 0.73 | DDB1 (0.46) | DDB1CRBNIKZF3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORP (US) | 2017-12-21 | — | — | US | disclosed |
| US-9587281-B2 | Cereblon isoforms and their use as biomarkers for therapeutic treatment | CELGENE CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CELGENE CORPORATION | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362660-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | DDB1 1337/4885CRBN 1/4885IKZF3 1569/4885 |
| US-20150152511-A1 | CEREBLON ISOFORMS AND THEIR USE AS BIOMARKERS FOR THERAPEUTIC TREATMENT | CRBN, CDR2, PMP22 | DDB1 1337/4885CRBN 1/4885IKZF3 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.